Elanco

Elanco, established in 1954, stands as a leading entity within the global animal health sector. Publicly traded under the ticker NYSE: ELAN, the company is dedicated to the research, development, manufacturing, and commercialization of sophisticated pharmaceutical products and vaccines designed for both companion animals and livestock. By focusing on veterinary medicine, disease prevention, and sustainable health solutions, Elanco addresses critical needs in the agricultural and pet care markets, maintaining a solid foundation for long-term growth and innovation.

The company operates with a substantial workforce of 5,000-10,000 employees, managing a complex operational network that spans 44 distinct global locations. Elanco utilizes its proprietary innovation platform to deliver high-quality veterinary medicine and health products to a diverse international client base. Learn about Elanco's global headquarters for detailed information regarding their primary corporate facility in Greenfield, Indiana, and their broader geographic footprint that supports their extensive supply chain and distribution capabilities.

Financially, Elanco reports annual revenue of $4.9B, positioning the firm as a major competitor against industry giants such as Zoetis, Covetrus, and Boehringer Ingelheim. The organization continues to prioritize strategic investments in research and development to address the evolving challenges of the veterinary sector. Meet Elanco's team to explore their leadership structure and deep organizational expertise, or Explore financial highlights for a comprehensive overview of their fiscal performance, debt structure, and recent funding history.